octob
joint
anrsnih
workshop
held
mucos
immun
hivaid
vaccin
veyrierdulac
franc
goal
meet
discuss
recent
develop
understand
viral
entri
dissemin
mucos
surfac
rational
design
vaccin
elicit
mucos
immun
respons
variou
rout
immun
type
immun
respons
elicit
lesson
drawn
exist
vaccin
viral
mucos
infect
recent
failur
merck
vaccin
attempt
mucos
immun
siv
report
summar
main
concept
conclus
came
meet
mucos
immun
system
especi
genit
gastrointestin
tract
import
target
hiv
infect
develop
hiv
vaccin
exclud
parenter
transmiss
virtual
infect
acquir
across
mucos
surfac
anorect
mucosa
vagin
mucosa
less
frequent
oral
mucosa
mucos
immun
system
particularli
mucosaassoci
lymphoid
tissu
malt
genit
tract
gutassoci
lymphoid
tissu
galt
repres
import
target
replic
reservoir
establish
lymphoid
tissu
destruct
prospect
design
vaccin
elicit
protect
mucos
immun
hiv
site
infect
discuss
joint
anrsnih
meet
octob
veyrier
du
lac
franc
light
stateoftheart
knowledg
mucos
immun
system
specif
characterist
biolog
viru
entri
lesson
learnt
vaccin
develop
human
mucos
infect
particip
time
meet
impact
recent
announc
interrupt
step
phambili
trial
merck
adenoviru
hiv
vaccin
eager
discuss
concept
methodolog
issu
field
vaccinolog
organ
mucosaassoci
immun
system
earli
involv
hiv
infect
review
depth
jan
holmgren
univers
sweden
point
contrari
gener
accept
belief
common
mucos
immun
system
best
gross
overestim
thu
immun
oral
rout
induc
mucos
immun
upper
part
intestin
mammari
gland
lower
part
gut
immun
nasal
rout
induc
mucos
immun
respons
respiratori
tract
femal
genit
tract
immun
rectal
rout
induc
mucos
immun
rectum
lower
part
gut
immun
vagin
rout
induc
mucos
immun
vagina
holmgren
colleagu
investig
potenti
sublingu
sl
immun
induct
mucos
immun
respons
shown
sl
administr
prototyp
antigen
togeth
cholera
toxin
adjuv
induc
broad
rang
immun
respons
lung
tissu
system
organ
recent
demonstr
respons
respiratori
gastrointestin
genit
tract
well
system
follow
sl
immun
sever
regist
vaccin
administ
oral
rout
live
oral
polio
inactiv
oral
cholera
live
oral
typhoid
fever
rotaviru
vlp
live
vaccin
must
achiev
delic
balanc
overattenu
underattenu
effect
yet
safe
addit
oral
vaccin
may
less
immunogen
tropic
countri
due
varieti
reason
higher
preval
intestin
helminth
infect
vitamin
zn
defici
impair
gut
restor
possibl
immun
exhaust
intestin
flora
nonliv
mucos
vaccin
requir
appropri
adjuv
elicit
strong
immun
respons
still
major
hurdl
cholera
toxin
ct
e
coli
heatlabil
toxin
lt
two
potent
mucos
adjuv
help
induc
cell
respons
remain
toxic
use
human
vaccin
effort
made
engin
less
toxic
form
adjuv
cpg
link
ctb
subunit
shown
promis
induc
good
chemokin
respons
fabienn
univers
nice
nice
franc
also
report
sever
approach
current
progress
induc
mucos
ctl
respons
protein
antigen
topic
intravagin
sublingu
administr
use
b
subunit
ct
ctb
colink
protein
antigen
cpg
oligodeoxynucleotid
lymphocyt
traffick
pattern
regul
select
express
adhes
molecul
peripher
mucos
lymphat
tissu
permit
segreg
immunolog
memori
caus
antigenprim
b
cell
return
specif
anatom
see
front
matter
destin
commit
exhibit
peripher
mucos
immun
tissu
specif
control
chemokin
home
receptor
present
mucos
tissu
instanc
report
rodrigo
mora
mass
gener
hospit
boston
usa
cell
instruct
express
guthom
receptor
integrin
chemokin
receptor
activ
dendrit
cell
dc
galt
gut
dc
dc
tissu
abil
gut
dc
imprint
guttrop
cell
b
cell
lie
abil
produc
store
retino
acid
ra
vitamin
metabolit
simpl
stimul
cell
antibodi
presenc
ra
induc
express
guthom
receptor
abil
gut
dc
secret
ra
probabl
consequ
intim
contact
intestin
epitheli
cell
also
metabol
vitamin
ra
interestingli
ra
also
synerg
induc
igaasc
thu
galtdc
ra
shape
gut
mucos
immun
maria
rescigno
european
institut
oncolog
milan
itali
emphas
import
cross
talk
dc
epitheli
cell
mucos
homeostasi
intestin
epitheli
cell
tightli
integr
mucos
immun
system
dc
mucos
tissu
educ
surround
epitheli
cell
suppress
inflamm
promot
immunolog
toler
uneduc
dc
recruit
peyer
patch
blood
respons
pathogen
attack
initi
inflamm
trigger
activ
immun
respons
invad
mucos
immun
system
therefor
difficult
task
maintain
fragil
balanc
activ
specif
immun
respons
fight
harm
pathogen
suppress
avoid
undesir
immun
reaction
self
harmless
antigen
usual
present
intestin
lumen
dominiqu
kaiserlian
cervi
lyon
franc
discuss
mucos
skin
dc
induc
cell
immun
toler
differ
function
properti
base
upon
lineag
tissu
local
contrari
gener
belief
resid
epitheli
tissu
dc
includ
lc
respons
cell
prime
fact
induc
peripher
toler
dc
newli
recruit
mucocutan
tissu
danger
signal
provid
pathogen
adjuv
directli
induc
prime
differenti
cell
cytolyt
effector
cell
vivo
recent
advanc
knowledg
dynam
function
epitheli
tissu
dc
provid
basi
screen
novel
cell
adjuv
like
dnfb
measl
viru
np
protein
cpg
oligodeoxynucleotid
flagellin
cholera
toxin
elicit
cell
crossprim
absenc
cell
help
increas
product
epitheli
cell
promot
recruit
dc
epithelia
per
brandtzaeg
univers
oslo
oslo
norway
extens
studi
mucos
immun
variou
immunodefici
describ
iga
transloc
gut
lumen
onto
mucos
surfac
trachea
bronchi
genit
tract
iga
pump
wherea
igg
leak
blood
vessel
stay
insid
tissu
parenchyma
includ
lung
knockout
mice
lack
secretori
iga
siga
sigm
exhibit
decreas
resist
cholera
toxin
pathogen
colon
gut
show
compensatori
increas
number
cytotox
activ
intraepitheli
lymphocyt
iel
cellular
arm
mucos
immun
iel
involv
antimicrobi
defenc
also
major
effector
oral
toler
secret
maintain
state
toler
note
fact
mucos
high
reg
cell
significantli
increas
number
intestin
mucosa
patient
also
show
elev
intestin
iga
level
paramet
level
becom
normal
initi
antiretrovir
therapi
discuss
thoma
schneider
la
berlin
germani
probabl
reflect
involv
mucos
homeostat
mechan
oper
gut
aid
patient
respons
opportunist
infect
mucos
transmiss
infect
mediat
exposur
infecti
viru
particl
probabl
also
infect
cell
within
mucos
secret
transmiss
critic
depend
upon
effici
transfer
infecti
viru
particl
across
mucos
epithelium
provid
access
viru
reach
intraor
subepitheli
dc
macrophag
andor
cell
express
viral
coreceptor
multipl
mechan
mucos
transmiss
propos
includ
direct
infect
epitheli
cell
transcytosi
epitheli
cell
andor
special
cell
epitheli
transmigr
donor
cell
uptak
intraepitheli
langerhan
cell
lc
dendrit
cell
dc
entri
via
epitheli
microabras
ulcer
architectur
mucos
epithelium
actual
dictat
mechan
hiv
transmiss
cell
transfer
transcytosi
main
rout
hiv
penetr
across
simpl
columnar
epithelium
line
endocervix
rectum
gastrointestin
tract
importantli
mucos
epitheli
cell
transcytosi
tissu
entri
substanti
inhibit
antibodi
underscor
potenti
vaccineinduc
inhibit
mucos
infect
report
meet
philip
smith
univers
alabama
birmingham
al
usa
hiv
penetr
first
layer
stratifi
squamou
epithelium
oral
caviti
oesophagu
anu
vagina
exocervix
break
epitheli
barrier
taken
transport
dcslc
lower
layer
epithelium
although
male
circumcis
report
reduc
male
acquisit
hiv
mechan
hiv
transmiss
via
pluristratifi
mucosa
foreskin
associ
lc
remain
unclear
recent
studi
suggest
activ
sampl
lumin
viru
lc
follow
migrat
epithelium
type
cell
initi
infect
thu
depend
anatom
site
viral
entri
therefor
import
taken
account
hiv
vaccin
develop
follow
cervicovagin
infect
endocerv
ectocerv
vagin
subepitheli
dc
rapidli
take
migrat
region
tcell
area
infect
lymphocyt
genit
macrophag
express
also
rapidli
take
hiv
support
replic
amplifi
infect
genit
cell
time
replic
viru
initi
local
innat
immun
respons
resid
dc
secret
meant
control
viral
replic
howev
also
trigger
inflammatori
respons
bring
cell
fuel
expans
spread
infect
local
distal
philip
smith
univers
alabama
birmingham
al
usa
discuss
detail
time
cours
earli
event
viral
entri
gut
genit
tissu
establish
eleg
mucos
explant
model
dissect
sequenc
event
cell
type
involv
intestin
mucosa
ec
dc
seem
take
viru
earli
min
inocul
also
summar
differ
tissu
architectur
receptor
express
variou
mucos
site
suggest
differ
mechan
entri
site
intestin
rectum
colon
endocervix
line
monostratif
columnar
epitheli
cell
wherea
vagina
ectocervix
anu
line
squamou
epithelium
intestin
macrophag
contrari
vagin
macrophag
express
support
infect
replic
viru
inabl
replic
cell
due
exclus
lack
second
receptor
express
contrast
lymphocyt
gut
lamina
propria
express
earliest
major
target
hiv
siv
infect
result
rapid
extens
deplet
memori
cell
galt
furthermor
analysi
lymphoid
nonlymphoid
organ
siv
infect
chines
rhesu
macaqu
infect
siv
year
shown
mesenter
lymph
node
constitut
main
viru
reservoir
infect
shown
rapidli
induc
enteropathi
bowel
inflamm
increas
gut
permeabl
propos
disrupt
gut
mucos
barrier
function
allow
transloc
microb
microbi
product
bacteri
lipopolysaccharid
lp
bodi
interior
result
chronic
system
immun
activationt
cell
exhaust
fuel
hiv
diseas
progress
interestingli
report
guido
silvestri
univers
pennsylvania
philadelphia
pa
usa
siv
infect
natur
host
sooti
mangabey
african
green
monkey
result
system
tcell
deplet
spite
high
level
persist
viru
replic
natur
nonpathogen
state
also
associ
rapid
deplet
cell
gut
respiratori
tract
similar
magnitud
observ
pathogen
hivsiv
infect
howev
deplet
occur
context
limit
enter
patholog
lead
system
immun
activ
earli
deplet
gut
cell
either
recuper
recruit
cell
achiev
homeostat
balanc
low
level
immun
stimul
maintain
nonpathogen
statu
natur
host
relev
may
observ
sivinfect
sooti
mangabey
keep
intact
gut
cell
popul
known
play
protect
role
infect
wherea
sivinfect
rhesu
macaqu
infect
human
result
deplet
cell
galt
loss
cell
gut
might
key
chronic
immun
activ
seen
siv
hiv
infect
fact
nonpathogen
state
natur
host
reach
absenc
appar
immunolog
control
viru
replic
emphas
tremend
challeng
artifici
induc
aid
vaccin
type
protect
immun
select
despit
thousand
year
evolutionari
pressur
lentivirus
primat
immun
system
thoma
hope
northwestern
univers
chicago
il
usa
present
studi
elucid
mechan
sexual
transmiss
hivsiv
human
simian
genit
tissu
explant
visual
movement
photoactiv
gfplabel
viru
studi
demonstr
first
barrier
viru
penetr
cervicovagin
mucu
impair
diffus
viru
crypt
endocervix
penetr
virion
could
observ
within
h
interstiti
space
differenti
squamou
epitheli
cell
well
subbas
milieu
columnar
endocerv
epithelium
coloc
lc
cell
viral
replic
macaqu
infect
intravagin
inocul
siv
also
studi
ashley
haas
univers
minnesota
minneapoli
mn
usa
develop
vagin
infect
model
studi
earli
event
system
dissemin
viru
exploit
local
innat
respons
bring
suscept
host
cell
fuel
expans
spread
infect
local
distal
suggest
mucos
barrier
effect
limit
initi
infect
occur
breach
protect
barrier
initi
limit
small
number
local
foci
submucosa
trigger
local
inflammatori
respons
character
influx
pdc
secret
subsequ
signal
influx
cell
fuel
progress
expans
spread
infect
infect
remain
local
hour
day
spread
drain
intern
iliac
lymph
node
day
spleen
lymph
node
day
rectal
infect
may
even
shorter
disrupt
epitheli
surfac
thu
interrupt
hiv
infect
expans
vaccin
strategi
need
effect
earliest
stage
mucos
infect
immun
system
must
capabl
respond
rapidli
curtail
establish
selfpropag
infect
gener
agreement
meet
order
provid
effect
immun
protect
relev
mucos
surfac
prevent
hiv
vaccin
certainli
need
elicit
product
antibodi
iga
genit
mucos
surfac
gut
igg
transud
system
compart
mucos
tissu
togeth
cytotox
cell
clear
mucos
infect
prevent
system
viru
spread
adapt
humor
immun
defenc
mucos
surfac
larg
extent
mediat
secretori
iga
siga
predomin
immunoglobulin
class
human
extern
secret
recogn
neutral
intestin
siga
antibodi
correl
immun
enter
viru
infect
report
morgan
bomsel
institut
cochin
pari
franc
mucos
iga
antibodi
specif
envelop
shown
block
mucos
hiv
entri
vitro
highli
expos
iggseroneg
hesn
women
repeat
unprotect
sex
hiv
partner
remain
seroneg
shown
harbour
siga
specif
conserv
determin
hiv
envelop
cervicovagin
secret
siga
block
cell
infect
vitro
well
transcytosi
viru
epitheli
barrier
librari
iga
monoclon
antibodi
deriv
cervic
b
cell
hesn
woman
donor
screen
result
clone
provid
monoclon
antibodi
target
heptad
repeat
other
target
ctermin
amino
acid
peptid
membran
proxim
extern
region
mper
categori
monoclon
antibodi
abl
block
transcytosi
crossclad
fashion
iga
fab
fragment
neutral
clade
b
isol
macrophag
well
cell
assay
interestingli
convers
igg
fab
accompani
loss
neutral
activ
convers
convers
igg
monoclon
antibodi
iga
fab
increas
neutral
potenc
confer
antibodi
potent
transcytosisblock
activ
although
hiv
vaccin
candid
far
elicit
mucos
iga
respons
either
poorli
immunogen
administ
parenter
without
appropri
adjuv
specif
design
induc
cytotox
lymphocyt
recommend
measur
iga
includ
futur
vaccinechalleng
studi
macaqu
model
howev
sever
challeng
obtain
reliabl
quantit
mucos
iga
discuss
pamela
kozlowski
louisiana
state
univers
new
orlean
la
usa
iga
measur
often
give
high
background
due
high
glycosyls
iga
make
molecul
sticki
quantif
iga
antibodysecret
cell
asc
biopsi
sampl
mucos
tissu
would
optim
often
unpract
measur
proport
iga
antibodysecret
cell
blood
easier
determin
number
iga
lymphoblast
destin
specif
mucos
site
analysi
antibodi
secret
collect
mucos
surfac
viral
exposur
often
occur
inform
howev
collect
method
mucos
secret
clearli
need
standard
collect
secret
absorb
weckcel
spong
seem
far
superior
collect
lavagewash
also
problem
lack
appropri
siga
refer
standard
convent
chromogen
elisa
recombin
envelop
protein
whole
viral
lysat
use
success
measur
virusspecif
iga
antibodi
cervicovagin
rectal
secret
adult
macaqu
human
provid
elisa
measur
total
iga
also
includ
analysi
determin
certainti
whether
secret
contain
signific
level
specif
siga
express
result
ng
specif
iga
per
g
total
iga
sampl
issu
need
consid
design
studi
analyz
mucos
iga
respons
role
lymphocyt
discuss
depth
throughout
meet
given
fact
adenoviru
hiv
merck
vaccin
design
elicit
strong
cell
respons
proven
ineffect
natur
protect
antisivmac
cell
immun
genit
tract
monkey
immun
discuss
meritxel
univers
california
davi
ca
usa
vaccin
monkey
live
attenu
provid
protect
uncontrol
viral
replic
vagin
challeng
pathogen
sivmac
protect
anim
show
littl
igg
iga
vagin
secret
show
polyfunct
gagspecif
ctl
genit
tract
howev
mere
presenc
hivspecif
mucos
cell
ensur
protect
infect
diseas
mucos
cell
detect
ex
vivo
semen
rectal
cervic
biopsi
volunt
vaccin
merck
adenoviru
hiv
vaccin
test
hvtn
even
though
vaccineinduc
hivspecif
cellular
immun
respons
well
sivspecif
cellular
respons
monkey
vaccin
vaccin
effect
prevent
hiv
infect
high
risk
volunt
becam
infect
spite
vaccin
discuss
juli
mcelrath
univers
washington
seattl
wa
usa
still
unclear
vaccin
fail
provid
qualiti
tcell
respons
necessari
effici
control
viru
replic
although
merck
vaccin
elicit
hivspecif
produc
cell
measur
indic
whether
cell
capabl
effici
lyse
virusinfect
cell
experiment
studi
recombin
vaccin
administ
oral
intranas
monkey
show
correl
protect
sivmac
intrarect
challeng
elispot
tcell
prolif
respons
peripher
blood
lymphocyt
live
attenu
shiv
vaccinesiv
vagin
challeng
studi
report
meritxel
see
protect
macaqu
found
vagin
gagspecif
polyfunct
ctl
secret
two
four
cytokin
well
vagin
cell
polycytokin
respons
cytolyt
activ
barbara
shacklett
univers
california
davi
ca
usa
elabor
polyfunction
hivspecif
tcell
respons
human
rectal
mucos
cell
elit
control
defin
individu
less
copiesml
plasma
viral
rna
absenc
antiretrovir
therapi
found
unusu
strong
complex
mucos
cell
respons
rectal
biopsi
tissu
mucos
cell
express
multipl
cytokin
chemokin
granzym
respons
hiv
gag
peptid
studi
suggest
polyfunct
cell
like
play
major
role
immun
surveil
gut
mucosa
addit
studi
french
cohort
hiv
control
also
show
system
cell
popul
particular
phenotyp
abl
suppress
viral
product
hla
restrict
manner
jean
oi
delfraissi
kremlin
franc
comment
one
elit
control
french
cohort
superinfect
abl
control
second
infect
jay
berzofski
nih
bethesda
md
usa
present
studi
mice
macaqu
highlight
role
ctl
avid
compartment
studi
demonstr
high
avid
mucos
ctl
correl
delay
viral
dissemin
intrarect
challeng
site
blood
stream
mucos
immun
macaqu
compar
function
activ
ctl
site
proxim
distal
site
immun
intrarect
vs
subcutan
rout
immun
mice
induc
tetram
bind
cell
gut
mucosa
howev
ir
immun
much
better
induc
ifngammasecret
cell
mucos
site
dc
produc
dc
found
proxim
site
immun
thu
protect
correl
high
avid
function
ctl
tetramerbind
cell
site
viral
replic
high
avid
ctl
best
induc
immun
proxim
site
protect
need
studi
linda
saif
ohio
state
univers
wooster
oh
usa
mucos
immun
porcin
respiratori
coronaviru
prcv
pig
model
similarli
reveal
prcv
infect
respiratori
tract
fail
induc
protect
anoth
mucos
site
intestin
tract
confirm
function
compartment
within
mucos
immun
system
concept
highli
relev
hiv
vaccin
reinforc
need
understand
mucos
traffick
pathway
use
optim
primeboost
vaccin
strategi
induc
antibodi
cell
high
avid
broad
antivir
activ
target
protect
multipl
hivsuscept
mucos
tissu
lucia
lopalco
san
raffael
institut
milan
itali
report
small
number
hesn
women
elicit
mucos
antibodi
direct
domin
chemokin
receptor
use
antibodi
appear
downregul
express
may
prevent
entri
target
cell
although
induct
antibodi
requir
break
b
cell
toler
could
achiev
mean
novel
vaccin
vector
coupl
suitabl
adjuv
formul
appropri
immun
schedul
studi
biolog
featur
protect
role
antibodi
gener
suitabl
immun
strategi
could
essenti
learn
break
immun
toler
elicit
broad
hivblock
system
well
mucos
immun
wide
assum
effect
hiv
vaccin
need
provid
cellular
humor
immun
respons
also
assum
prevent
infect
requir
immun
site
exposur
case
mucos
site
one
induc
immun
effect
antigen
deliveri
vehicl
best
rout
immun
necessari
immun
mucos
achiev
mucos
immun
necessari
use
adjuv
question
part
remain
unansw
mani
issu
discuss
workshop
summar
sever
deliveri
vehicl
develop
mucos
vaccin
liposom
immunostimul
complex
iscom
viruslik
particl
vlp
denis
nardellihaefling
chuv
lausann
switzerland
review
develop
vlp
effici
prevent
genit
infect
human
papillomaviru
hpv
type
caus
anogenit
wart
hpv
lead
caus
cancer
cervix
hpv
strictli
epitheliotrop
thu
protect
immun
requir
induct
neutral
antibodi
anogenit
secret
three
vlp
intramuscular
immun
regimen
readili
induc
elev
level
antihpv
neutral
igg
uterin
cervix
level
antibodi
howev
decreas
sever
fold
time
ovul
may
theoret
impact
longterm
efficaci
vaccin
also
confirm
suggest
hiv
vaccin
regimen
need
consid
reproduct
hormon
fluctuat
women
obtain
protect
across
mucos
barrier
system
immun
siga
titer
hand
declin
ovul
although
proven
difficult
practic
stimul
strong
siga
immun
respons
protect
mucos
administr
antigen
intranas
immun
known
induc
siga
antibodi
respons
airway
femal
genit
tract
prompt
attempt
vaccin
women
genit
hpv
infect
aerosol
administr
current
vlp
vaccin
import
studi
intranas
rout
immun
develop
hiv
vaccin
also
help
elucid
whether
mucos
immun
requir
achiev
sustain
protect
mucos
site
infect
oral
immun
induc
strong
siga
respons
small
intestin
proxim
colon
mammari
gland
poorli
effici
elicit
similar
respons
distal
segment
gut
respiratori
reproduct
tract
rotaviru
gnotobiot
piglet
model
discuss
linda
saif
ohio
state
univers
wooster
oh
usa
initi
vaccin
prime
must
take
place
oral
rout
live
attenu
vaccin
effect
howev
subsequ
boost
immun
effici
achiev
nonrepl
vaccin
vlp
administ
nasal
rout
dna
immun
intramuscular
rout
primeboost
strategi
induc
high
level
intestin
neutral
siga
memori
b
cell
two
major
correl
protect
regard
hiv
vaccin
lesson
suggest
rotaviru
model
suggest
effect
strategi
employ
need
optim
prime
immun
respons
multipl
mucos
site
genitourinari
rectal
boost
assist
amplifi
induc
memori
respons
multipl
boost
shown
provid
protect
genet
diverg
rotaviru
strain
final
requir
induc
neutral
antibodi
mucos
surfac
critic
import
shown
infect
dissemin
faster
time
requir
initi
product
ctl
recal
respons
mention
sublingu
immun
also
could
promis
rout
induc
antibodi
tcell
respons
systemat
well
multipl
mucos
site
includ
gastrointestin
tract
genit
tract
jorma
hinkula
karolinska
institutet
stockholm
sweden
report
use
multigen
env
gag
pol
tat
rev
nef
dna
prime
administ
mice
without
cation
adjuv
gmcsf
pcpp
follow
booster
immun
peptid
recombin
protein
live
recombin
mva
vlp
ad
varieti
adjuv
pcpp
cpg
oligodeoxynucleotid
gmcsf
cation
lipid
adjuv
enhanc
intranas
dna
prime
follow
heterolog
vlp
boost
site
eurocrin
mucos
adjuv
result
higher
ex
vivo
neutral
activ
heterolog
bclade
viral
isol
potent
broadest
hivneutr
mucos
immun
respons
obtain
vaccin
deliv
first
cours
immun
regimen
onto
mucos
surfac
presenc
mucos
adjuv
pcpp
although
inclus
gmcsf
vaccin
gave
rise
higher
avid
antibodi
addit
cytokin
appear
detriment
elicit
cellular
respons
mechan
part
due
innat
immun
nk
cell
appear
play
role
reduc
elispot
respons
vaccin
insert
seri
compar
immun
experi
michael
vajdi
novarti
emeryvil
ca
usa
administ
vaccin
subunit
delet
hypervari
loop
either
intranas
rout
presenc
genet
detoxifi
lt
intramuscular
rout
presenc
adjuv
show
optim
regimen
induc
vagin
system
iga
igg
respons
mice
nonhuman
primat
one
intranas
prime
immun
follow
coupl
intramuscular
booster
immun
true
gag
dna
plasmid
plg
particl
combin
intranasalintramuscular
primeboost
regimen
effici
induc
respons
gag
specif
cell
antibodi
note
vagin
immun
provid
best
result
term
protect
appear
correl
higher
number
gagspecif
elispot
drain
lymph
node
clearli
data
rout
primeboost
evalu
respons
protect
need
pursu
immun
protect
mucos
surfac
may
requir
differ
vaccin
strategi
men
women
ie
genderspecif
vaccin
lawrenc
stanberri
univers
texa
galveston
tx
usa
discuss
result
gsk
herpesviru
glycoprotein
vaccin
clinic
trial
vaccin
afford
protect
genit
herp
diseas
hsvneg
women
protect
men
util
mous
model
shown
vaccin
tcell
deplet
anim
protect
bcell
defici
anim
suggest
protect
due
vaccineinduc
antibodi
rais
possibl
gender
differ
observ
human
trial
may
due
vaccineinduc
antibodi
present
site
exposur
women
men
femal
genit
tract
present
opportun
immun
similar
fashion
induct
mucos
immun
protect
mucos
viru
challeng
test
nonhuman
primat
model
immun
sever
vaccin
candid
dna
live
vector
subunit
vaccin
without
adjuv
follow
variou
protein
booster
administ
variou
rout
paul
johnson
new
england
primat
research
center
harvard
medic
school
southborough
usa
compar
efficaci
multigen
siv
gag
pol
env
rev
tat
nef
dnamva
primeboost
vaccin
regimen
live
attenu
siv
nef
vaccin
induc
mucos
respons
siv
protect
femal
macaqu
lowdos
vagin
pathogen
sivmac
challeng
challeng
repeat
twice
day
weekli
interv
week
dnamva
primeboost
regimen
result
rel
high
level
gagspecif
cell
mucos
site
level
neutral
igg
antibodi
lower
serum
vagin
secret
compar
nef
vaccin
anim
monkey
higher
titer
siv
specif
iga
requir
greater
number
challeng
becom
infect
upon
infect
viral
load
set
point
dnamva
vaccin
anim
log
lower
control
infect
monkey
wherea
viral
load
siv
nef
vaccin
anim
remain
low
log
control
often
limit
detect
although
nef
vaccin
induc
good
peripher
cell
respons
compar
dnamva
vaccin
show
quit
greater
protect
efficaci
rais
note
caution
regard
use
pbmcbase
immun
respons
measur
correl
protect
martha
martha
univers
california
davi
ca
usa
concentr
develop
vaccin
neonat
goal
prevent
breast
milk
transmiss
resourcepoor
countri
three
vaccin
regimen
compar
newborn
monkey
vaccin
oral
birth
monkey
either
vaccin
recombin
mvagag
pol
env
siv
vaccin
given
im
recombin
vesicular
stomat
viru
vsv
gag
pol
env
siv
given
oral
oral
vsv
vaccin
follow
week
age
mva
vaccin
boost
im
protect
seen
arm
low
dose
oral
challeng
although
vsvmva
regimen
elicit
sivspecif
system
igg
iga
well
cell
respons
pbmc
tonsillar
lymphoid
tissu
commun
call
attent
specif
challeng
vaccin
must
overcom
protect
hiv
breast
milk
transmiss
promis
approach
describ
marjori
robertguroff
nih
bethesda
md
usa
base
oral
administr
wildtyp
virus
via
enter
coat
capsul
strategi
use
year
protect
us
militari
recruit
acut
respiratori
diseas
rhesu
monkey
immun
replicationcompet
siv
env
rev
gag
nef
recombin
host
rang
mutant
administ
intranas
oral
rout
follow
intramuscular
boost
siv
monophosphoryl
lipid
stabl
emuls
mplse
vaccin
strategi
gave
equival
signific
protect
homolog
intrarect
challeng
macaqu
exhibit
either
viremia
clear
viremia
control
viremia
threshold
detect
week
challeng
second
rectal
challeng
done
time
protect
anim
show
durabl
protect
wherea
three
show
decreas
viremia
compar
naiv
control
oral
nasal
administr
vaccin
elicit
sivspecif
cell
bronchial
alveolar
lavag
guthom
receptor
sivspecif
peripher
blood
cell
central
effector
memori
cell
respons
sivspecif
igg
iga
antibodi
mucos
secret
antibodi
neutral
could
mediat
antibodydepend
cellular
cytotox
adcc
durabl
protect
infect
associ
presenc
sivspecif
elispot
cell
prolif
respons
importantli
deplet
cell
lead
reemerg
viremia
anim
disappear
reappear
cell
restor
sivspecif
cellular
immun
howev
neither
elispot
prolif
cell
assay
perform
pbmc
prior
initi
challeng
predict
protect
observ
highlight
lack
predict
pbmc
immunolog
assay
need
reliabl
correl
protect
anoth
promis
approach
highlight
sylvain
fleuri
mymet
nyon
switzerland
describ
use
mper
ctermin
peptid
graft
onto
virosom
administ
intranas
intramuscular
combin
intranasalintramuscular
rout
femal
chines
rhesu
macaqu
although
sera
vaccin
anim
contain
high
level
mper
specif
igg
antibodi
possess
hiv
inhibitori
properti
rout
immun
induc
similar
level
iga
igg
antibodi
cervicovagin
secret
iga
could
recov
rectal
secret
contrast
sera
igg
antibodi
mucos
iga
antibodi
capabl
block
vitro
transcytosi
primari
clade
b
clade
c
viru
isol
purifi
iga
vagin
secret
also
found
neutral
primari
clade
b
viru
infect
ci
gml
immunizationchalleng
experi
rhesu
macaqu
plan
take
place
shortli
determin
antibodi
play
role
vivo
yve
franc
report
mucos
arm
recent
anrssponsor
phase
trial
anr
involv
three
administr
either
intranas
intravagin
rout
purifi
subunit
presenc
absenc
adjuv
dcchol
studi
perform
french
femal
volunt
show
feasibl
phase
trial
design
assess
mucos
respons
nasal
vagin
secret
import
question
discuss
meet
whether
anim
model
hiv
vaccin
reliabl
predict
success
induct
protect
immun
human
gener
rule
potenti
hiv
vaccin
candid
test
nhp
model
clinic
trial
carri
differ
rhesu
macaqu
indian
chines
origin
well
shiv
siv
strain
use
variou
nhp
studi
often
make
direct
comparison
studi
imposs
point
david
watkin
aid
vaccin
research
laboratori
madison
wi
usa
merck
vaccin
went
clinic
trial
shown
protect
nhp
model
howev
protect
macaqu
studi
mamua
posit
haplotyp
relat
spontan
control
siv
infect
challeng
use
shiv
strain
whose
hiv
sequenc
exactli
match
recombin
vaccin
vaccin
eventu
test
macaqu
challeng
anim
protect
infect
diseas
progress
suggest
made
futur
vaccin
efficaci
test
nhp
model
take
account
genet
origin
monkey
avoid
overrepresent
mhc
class
allel
mamu
vaccin
monkey
associ
spontan
control
siv
viremia
mimick
hla
allel
associ
control
replic
human
elit
control
importantli
vaccin
base
sivmac
reduc
viral
replic
log
set
go
forward
phase
iib
trial
also
effect
hiv
vaccin
need
provid
protect
global
divers
isol
demonstr
protect
heterolog
viru
challeng
becom
major
point
consid
great
need
develop
new
hiv
vaccin
strategi
would
effect
earliest
stage
mucos
infect
block
hiv
penetr
genit
gut
mucosa
better
understand
first
step
hiv
entri
infect
mucos
immun
respons
therefor
need
mucos
immun
system
highli
complex
compartmentalis
entir
deciph
contrari
earlier
belief
common
mucos
immun
system
appli
mucos
tissu
shown
case
recent
year
illustr
ashley
haas
univers
minnesota
minneapoli
usa
studi
discuss
summari
talk
robin
shattock
st
georg
hospit
london
uk
narrow
window
opportun
mucos
sivand
probabl
hivinfect
spread
site
entri
system
lymphoid
system
viru
transport
primari
infect
dc
target
cell
within
h
infect
dissemin
infect
local
lymph
node
take
perhap
day
even
less
depend
rout
infect
time
period
need
compar
known
day
take
reawaken
memori
immun
respons
vaccin
individu
therefor
strong
persist
neutral
antibodi
respons
prevent
hiv
infect
least
reduc
potenti
infecti
virion
mucos
surfac
still
desper
need
wherea
potent
specif
antivir
mucos
cell
respons
requir
prevent
viral
dissemin
obviou
appropri
anim
model
need
develop
well
ex
vivo
model
take
consider
role
coinfect
hormon
variat
femal
genit
tract
idea
mucos
transcytosisblock
andor
neutral
iga
antibodi
may
key
protect
infect
must
document
confirm
would
sublingu
intranas
rout
immun
advantag
regard
would
repeat
local
vagin
rectal
booster
immun
help
vari
opinion
whether
mucos
immun
site
infect
need
induc
andor
boost
protect
immun
respons
site
final
much
progress
made
field
mucos
vaccin
absenc
standard
protocol
sampl
collect
assay
measur
mucos
immun
respons
critic
urgent
need
evalu
mucos
immun
accur
reliabl
fashion
compar
respons
multipl
hiv
vaccin
global
scale
perhap
one
frequent
heard
observ
came
meet
standard
cell
assay
elispot
ic
andor
prolifer
assay
done
pbmc
predictor
protect
immun
recent
report
ron
desrosi
group
well
illustr
point
potent
protect
siv
challeng
provid
live
attenu
siv
infect
absenc
strong
antisiv
immun
respons
peripher
blood
wherea
opposit
highmagnitud
antisiv
immun
respons
peripher
blood
provid
dna
prime
recombin
poxviru
adenoviru
boost
provid
littl
protect
similar
challeng
similarli
cell
respons
identifi
elispot
intracellular
cytokin
stain
ic
assay
use
singl
high
concentr
peptid
pbmcderiv
cell
popul
often
fail
predict
recognit
cell
infect
escap
variant
virus
nevertheless
mani
present
underscor
need
induc
cell
respons
control
sivhiv
infect
accur
assess
antivir
activ
hivspecif
ctl
therefor
becom
crucial
step
evalu
vaccin
potenc
thu
use
viral
suppress
assay
test
function
cell
attempt
identifi
cell
popul
associ
control
infect
siv
hiv
control
well
studi
cell
transcriptom
proteosom
profil
advoc
rafik
sekali
canvac
montreal
canada
area
futur
activ
investig
also
would
import
studi
breadth
avid
virusspecif
iga
igg
develop
standard
assay
valid
function
whether
viral
transcytosisblock
virusneutr
assay
identif
reliabl
correl
protect
mucos
infect
remain
time
ever
number
one
quest
hiv
vaccinolog
